TRML

Tourmaline Bio Inc

Add to Watchlist

Advanced Chart

18.860

+0.63(3.456%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

18.890

Open

18.190

VWAP

18.54

Vol

82.67K

Mkt Cap

484.48M

Low

18.115

Amount

1.53M

EV/EBITDA(TTM)

Total Shares

25.69M

225.42M

EV/OCF(TTM)

P/S(TTM)

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is pacibekitug (TOUR006), a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is focused on two strategic paths for TOUR006, the first of which is cardiovascular inflammation. Its second strategic path is thyroid eye disease (TED). TED is an autoimmune disease characterized by autoantibody-mediated activation of the tissues surrounding the eye, causing inflammation and disfigurement which can be sight-threatening in severe cases.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.769

-10.61%

-0.976

+25.16%

-0.931

+36.95%

Estimates Revision

The market is revising Downward the revenue expectations for Tourmaline Bio, Inc. (TRML) for FY2025, with the revenue forecasts being adjusted by -10% over the past three months. During the same period, the stock price has changed by 5.84%.

Revenue Estimates for FY2025

Revise Downward

-10%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.37%

In Past 3 Month

Stock Price

Go Up

+5.84%

In Past 3 Month

9 Analyst Rating

192.36% Upside

Wall Street analysts forecast TRML stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRML is 55.14 USD with a low forecast of 35.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

192.36% Upside

Current: 18.860

Low

35.00

Averages

55.14

High

70.00

192.36% Upside

Current: 18.860

Low

35.00

Averages

55.14

High

70.00

Chardan Capital

Daniil Gataulin

Strong Buy

Initiates

$70

2025-04-23

Reason

Chardan Capital

Daniil Gataulin

Price Target

$70

2025-04-23

Initiates

Strong Buy

Reason

Chardan analyst Daniil Gataulin initiated coverage of Tourmaline Bio with a Buy rating and $70 price target. The firm cites the potential of the company's lead asset, the anti-IL6 antibody pacibekitug, in thyroid eye disease and atherosclerotic cardiovascular disease for the Buy rating. It also sees additional upside potential in abdominal aortic aneurysm.

Wedbush

Laura Chico

Buy

Maintains

$42 → $43

2025-03-14

Reason

Wedbush

Laura Chico

Price Target

$42 → $43

2025-03-14

Maintains

Buy

Reason

Wedbush initiated coverage of Tourmaline Bio with an Outperform rating and $42 price target.

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$49 → $50

2025-03-14

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$49 → $50

2025-03-14

Maintains

Strong Buy

Reason

Wedbush

Laura Chico

Buy

Initiates

$42

2025-03-06

Reason

Wedbush

Laura Chico

Price Target

$42

2025-03-06

Initiates

Buy

Reason

Wedbush initiated coverage of Tourmaline Bio with an Outperform rating and $42 price target.

LifeSci Capital

Jimmy Shan

Buy

Initiates

$58

2025-02-24

Reason

LifeSci Capital

Jimmy Shan

Price Target

$58

2025-02-24

Initiates

Buy

Reason

LifeSci Capital initiated coverage of Tourmaline Bio with an Outperform rating and $58 price target.

Guggenheim

Yatin Suneja

Strong Buy

Reiterates

n/a

2024-12-11

Reason

Guggenheim

Yatin Suneja

Price Target

n/a

2024-12-11

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Tourmaline Bio Inc (TRML.O) is -5.00, compared to its 5-year average forward P/E of -6.13. For a more detailed relative valuation and DCF analysis to assess Tourmaline Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.13

Current PE

-5.00

Overvalued PE

-3.62

Undervalued PE

-8.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

13.02

Current PS

71.21

Overvalued PS

38.76

Undervalued PS

-12.71